Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
Metrics: PDF 492 views | HTML 840 views | ?
Jean-David Fumet1,*, Aurélie Bertaut2,3, Leila Bengrine1, Patricia Lapierre3, Julie Vincent1, François Ghiringhelli1,2,3,* and Nicolas Falvo4
1Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
2Department of Epidemiology and Biostatistics, Georges François Leclerc Center, Dijon, France
3Center of Clinical Research, Georges François Leclerc Center, Dijon, France
4Department of Radiology, François-Mitterrand Teaching Hospital, Dijon, France
*These authors have contributed equally to this work
Jean-David Fumet, email: firstname.lastname@example.org
Keywords: angiogenesis; bevacizumab; capillary rarefaction; colorectal cancer
Received: October 20, 2017 Accepted: November 10, 2017 Published: December 01, 2017
Background: Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody targeting VEGF-A. It is currently used with chemotherapy as the first- or second-line therapy in metastatic colorectal cancer. Previous studies have showed that anti-angiogenic agents decrease capillary density. We evaluated the link between decreased capillary density and the response to bevacizumab-based chemotherapy.
Results: Overall, 43 patients with metastatic colorectal cancer treated with first-line bevacizumab-based chemotherapy were enrolled. At Day 90, progressive disease was observed in 12 patients (27.9%). All patients presented decreased capillary density. ROC analysis at different time points and capillary density variation showed a poor diagnostic performance regarding response at Day 90.
Materials and Methods: From 2013 to 2015, patients with metastatic colorectal cancer treated in our French cancer care center and eligible for bevacizumab with chemotherapy were enrolled in a prospective single-center study. Capillary density was assessed using capillaroscopy at Day 1, Day 15 and Day 30. Response to bevacizumab was assessed at Day90 according to CHUN criteria.
Conclusions: Capillary density measured using capillaroscopy is not a good predictor of the early response to bevacizumab-based chemotherapy. (NCT01810744).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.